Fig 1: The SE–TF regulatory network consisting of SMAD3, ETS1, and HOXB2 promotes the malignant phenotype of bladder cancer cells. (a) Migration, invasion, and proliferation of T24 cells following overexpression or silencing of SMAD3, ETS1, and HOXB2 measured by Transwell and CCK-8 assays. (b) Migration, invasion, and proliferation of T24 cells following transfection with sh-SMAD3, sh-SMAD3 + pcDNA3.1-ETS1, sh-SMAD3 + pcDNA3.1-HOXB2, or sh-SMAD3 + pcDNA3.1-ETS1 + pcDNA3.1-HOXB2 measured by Transwell and CCK-8 assays. *p < 0.05. The experiment was conducted three times independently.
Fig 2: The presence of SE–TF regulatory network consisting of SMAD3, ETS1, and HOXB2 in T24 cells. (a) H3K27ac intensity of SMAD3 in eight common malignant tumor cell lines analyzed by ChIP-PCR. (b) Expression of core TFs of bladder cancer (SMAD3, ETS1, and HOXB2) in T24 cells determined by RT-qPCR. (c) Silencing and overexpression efficiency of SMAD3, ETS1, and HOXB2 in T24 cells determined by western blot analysis. (d) Overexpression efficiency of SMAD3, ETS1, and HOXB2 in T24 cells determined by RT-qPCR. (e) Expression of other two TFs in T24 cells following silencing of any bladder cancer TFs determined by western blot analysis. (f) Expression of other two TFs in T24 cells following overexpression of any bladder cancer TFs determined by RT-qPCR. (g) Expression of other TFs in T24 cells following intervention with two types of bladder cancer TFs determined by western blot analysis. (h) Expression of other TFs in T24 cells following intervention with two types of bladder cancer TFs determined by RT-qPCR. (i) The binding of each TF to the promoter regions of the other two TFs analyzed by ChIP-PCR. *p < 0.05. The experiment was conducted three times independently.
Supplier Page from Abcam for Anti-ETS1 antibody